The European clinical experience with dothiepin since 1962 indicates that it is efficacious in the treatment of depression (neurotic, psychotic, and with concomitant anxiety) in dose of 75-200 mg/day. The side effects profile is similar to the tricyclic antidepressant drugs with significantly less anticholinergic side effects and cardiotoxicity than amitriptyline. The results of the current ongoing clinical trials in the United States with several hundred patients will more precisely define the efficacy, dosage and side effect profile of dothiepin.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of Clinical Psychiatry|
|Issue number||12 II|
|State||Published - Dec 1 1980|
ASJC Scopus subject areas
- Psychiatry and Mental health